Zogenix Sets IPO Range

Xconomy San Diego — 

San Diego’s Zogenix, which has developed a needle-free injector and drug for quick treating of migraines, has amended its IPO filing, saying it intends to raise about $78 million in its initial offering on Nasdaq. In its filing yesterday, Zogenix says it plans to offer 6 million shares priced between $12 and $14 a share. The stock will trade under the ticker symbol ZGNX. CEO Roger Hawley told me in August that the life sciences startup has raised nearly $200 million in venture capital from Domain Associates, Clarus Lifesciences, Scale Venture Partners, Thomas McNerney & Partners, Chicago Growth Partners, Abingworth Bioventures, and others.